Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-acellular pertussis (5-component) vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b vaccine
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a hexavalent combination vaccine containing a **5-component acellular pertussis vaccine** (DTaP5), **hepatitis B vaccine**, **inactivated poliovirus vaccine (IPV)**, and **Haemophilus influenzae type b (Hib) conjugate vaccine**. It induces active immunity against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, hepatitis B virus, and invasive Hib disease through antibody production against toxoids, inactivated pathogens, and surface antigens. Administered intramuscularly to infants starting at 6 weeks of age in a 3- or 4-dose series (depending on brand), it reduces injection burden compared to separate vaccines while maintaining comparable immunogenicity, though some studies note slightly lower responses for Hib and tetanus antigens. Branded as **Vaxelis** (Merck/Sanofi) in the US and **Infanrix hexa** internationally, it is a standard pediatric vaccine per CDC and WHO schedules.[2][6][7][9]
- Brand names
- Infanrix hexa
- Other names
- DTaP5-IPV-HepB-Hib vaccineDTaP-5-IPV-HepB-Hib vaccineDTaP 5-IPV-HepB-Hib vaccine6-in-1 vaccinediphtheria-tetanus-acellular pertussis-hepatitis B-poliovirus-haemophilus influenzae type b vaccine
02
Targets
PRN (Pertactin)TT (Tetanus toxoid)Diphtheria toxinFimbrial antigen type 3HBsAg (Hepatitis B surface antigen)WPV3 (Poliovirus type 3 capsid protein)FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria-tetanus-acellular pertussis (5-component) vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-acellular pertussis (5-component) vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b vaccine.